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Abstract
Two phase III clinical trials (CheckMate 141 and KEYNOTE 040) have independently demonstrated that overall survival
(OS) in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients, who have failed
platinum-based therapy, can be improved with anti-PD1 monotherapy. Treatment with nivolumab or pembrolizumab
in R/M HNSCC patients led to an improved OS with a hazards ratio (HR) of 0.70 (95%CI 0.51–0.96; p = 0.01) and HR of 0.
80 (95%CI 0.65–0.98, p = 0.0161), respectively, as compared to standard of care (SOC) chemo monotherapy regimens
(specifically, cetuximab, docetaxel, or methotrexate). The gain in OS was similar in both studies, underscoring the role
of anti-PD1 drugs in R/M HNSCC patients. One of the striking discrepancies between CheckMate 141 and KEYNOTE 040
was the OS observed in the control SOC arms (6.9 months median in KEYNOTE 040 versus 5.1 months in CheckMate
141), which inadvertently set a higher threshold in the bio-statistical analysis of KEYNOTE 040 so that the clinical
outcome of every patient was influential in the analysis. We perform a comparative analysis of the two studies to
identify potential factors in the control arm that can impact clinical trial bio-statistical outcomes and which may have
implications for future immunotherapy clinical trial designs.
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Overview of the phase III clinical trials
In the CheckMate 141 clinical trial sponsored by
Bristol-Myers Squibb (BMS) (NCT02105636), 361 re-
current and/or metastatic (R/M) head and neck squa-
mous cell carcinoma (HNSCC) patients were
randomized 2:1 to either nivolumab (N = 240) or
standard of care (SOC) chemo monotherapy (N =
121) [1]. The monotherapy treatment options in-
cluded weekly applications of either methotrexate 40
mg/m2, docetaxel 30 mg/m2, or cetuximab 250 mg/m2
(400 mg/m2 loading dose first). The patients in the
study were stratified based on prior cetuximab treat-
ment only. In the KEYNOTE 040 clinical trial spon-
sored by Merck Sharp and Dohme (MSD)
(NCT02252042), 495 R/M HNSCC patients were
randomized 1:1 to either pembrolizumab (N = 247) or
SOC chemo monotherapy (N = 248) [2–4]. The
monotherapy treatment options included methotrexate
40 mg/m2 weekly, docetaxel 75 mg/m2 every 3 weeks,
or cetuximab 250 mg/m2 weekly (400 mg/m2 loading
dose first). Stratification factors included p16 status
and a tumor proportion score (TPS) of PDL1 expres-
sion ≥ 50% or < 50%. In both of these studies, the
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primary bio-statistical endpoint was overall survival
(OS) in the intention-to-treat (ITT) population.
Factors impacting overall survival in the control
arms
One of the main differences between these two clinical
trials was the OS observed in the control SOC arms (6.9
months median in KEYNOTE 040 versus 5.1 months in
CheckMate 141). The 1.8-month difference in median
OS in the control arms may have had significant
bio-statistical implications for the endpoint analysis.
Patient selection
There were two important differences in the selection of
patients between these two trials. Although both trials
included patients with platinum refractory R/M HNSCC,
KEYNOTE 040 excluded patients who recurred or pro-
gressed within 3 months of previous multimodal therapy
containing platinum for locally advanced disease. Thus,
KEYNOTE 040 was excluding the rapidly progressing
patient population from the trial. In addition, in KEY-
NOTE 040, only 1.2% (N = 6 of 495) of the HNSCC pa-
tients had received ≥ 3 prior lines of therapy as
compared to 19.9% (N = 72 of 361) in CheckMate141.
Thus, in KEYNOTE 040, the population was less heavily
pre-treated and aggressive tumor growth characteristics
were excluded from the trial and these exclusion criteria
most likely contributed to the improved OS observed in
the control arm. This inadvertently set a higher thresh-
old in the bio-statistical analysis of KEYNOTE 040 so
that the clinical outcome of every patient was influential
in the analysis.
Differential distribution of SOC treatment regimens
In addition, even though the mono chemotherapy treat-
ment options in the SOC arms were the same in both
clinical trials, there were differences in the dosing and
the overall distribution of the patients in the SOC treat-
ment regimen received. Specifically, there were differ-
ences in the dosing of docetaxel. In the KEYNOTE 040
trial, docetaxel was given at 75 mg/m2 q3weeks whereas
in CheckMate 141 the docetaxel dose was 30mg/m2
qweek. Whether this difference in dosing of docetaxel
makes a difference is unclear but we may speculate that
the q3week dosing may be reserved for more robust
patients in KEYNOTE040. In addition, docetaxel q3
weeks has been reported as slightly more efficient in
terms of response rate or survival than the weekly
schedule in other sensitive tumor types, such as breast
and prostate cancer [5, 6]. There was also a higher per-
centage of patients who were treated with docetaxel
(42% versus 21%) and cetuximab (30% versus 11%) in
KEYNOTE 040 as compared to CheckMate 141, respect-
ively. In contrast, in CheckMate 141, there was a higher
number of patients who received methotrexate (38% ver-
sus 27% in KEYNOTE 040). While the CheckMate 141
trial was not designed to compare the three regimens
used in the SOC arm, docetaxel appeared to result in a
slightly improved OS as compared to patients receiving
methotrexate and cetuximab, although the overall num-
bers were small to be able to make definitive conclu-
sions. Thus, the difference in the number of R/M
HNSCC patients receiving docetaxel in KEYNOTE 040
as compared to methotrexate in CheckMate 141 may
have also contributed to the improved OS in the control
arms (6.9 months versus 5.1 months).
Subsequent treatment with immune checkpoint inhibitors
in the SOC arm
Both phase III trials had a subset of patients who were
allocated to the SOC arm but did not receive SOC ther-
apy. In KEYNOTE 040, 5.6% (N = 14 of 248) of patients
as compared to 8.2% (N = 10 of 121) of patients in
CheckMate 141 did not receive SOC therapy. Most im-
portantly, the treatment option provided at the time of
progression was very different between the two clinical
trials based on the timing of the studies and most likely
had a large influence in the OS observed in the control
arms. At the time of the KEYNOTE 040 study, both
pembrolizumab and nivolumab were Food and Drug Ad-
ministration (FDA) approved for the treatment of R/M
HNSCC patients in contrast to when the CheckMate
141 study had completed, in which an immune check-
point inhibitor (ICI) was only accessible through clinical
trials. In CheckMate 141, the data cutoff point for the
analyses of OS, progression free survival (PFS), and
safety was December 18, 2015 with a median duration of
follow-up for OS of 5.1 months (range, 0 to 16.8) and
data on rate of response was based on a cutoff of May 5,
2016. Pembrolizumab had received FDA approval in Au-
gust of 2016 and nivolumab in November of 2016. KEY-
NOTE 040 had a data cutoff point of May 15, 2017.
Correspondingly, in KEYNOTE 040, 12.5% (31 of 248)
of patients in the SOC arm received an ICI at the time
of clinical progression. The impact of receiving subse-
quent ICI in the SOC arm had a significant impact on
median OS, with patients in the SOC arm receiving sub-
sequent ICI having a prolonged median OS of 20.1
months (N = 15, 95% CI: 14.0-NE months) as compared
to a median OS of 9.7 months (N = 58, 95% CI: 9.0–11.3
months) in patients who went on to receive a non-ICI
therapy or a median OS of 4.5 months (N = 134, 95% CI:
3.7–5.0 months) in patients who received no subsequent
therapy.
Patient selection based on PD-L1 expression
These trials also highlight the importance of patient
selection in clinical trial design and raises the question
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whether patient selection based on expression of a prog-
nostic biomarker, such as PD-L1, should be considered
as an eligibility criteria for future PD-1/PD-L1 targeted
clinical trials. Both of the phase III clinical studies
provide insight into this question through a sub-analysis
performed on OS based on PD-L1 expression > 1%
within the tumor microenvironment. In KEYNOTE 040,
using a PD-L1 combined positive score (CPS) of ≥ 1,
which is defined by PD-L1 expression on both immune
and tumor cells, the HR was 0.74 (95% CI: 0.58–0.93,
p = 0.0049) with a median OS of 8.7 months with
anti-PD1 treatment. Similarly, in CheckMate 141, a
PD-L1 tumor cell expression score of ≥ 1% resulted in a
HR of 0.55 (95% CI: 0.36–0.83) with a median OS of 8.7
months. If PD-L1 expression serves as a true prognostic
biomarker of response for PD-1 therapy, an increasing
percentage of PD-L1 expression within the tumor micro-
environment should correlate with improved OS and
this is indeed what is observed. In KEYNOTE 040, a
PD-L1 tumor proportion score (TPS) of ≥ 50% improved
the HR to 0.53 (95% CI: 0.35–0.81, p = 0.0014) with a
median OS of 11.6. Correspondingly, the complete re-
sponse (CR) rates also increase with PD-L1 expression.
In KEYNOTE 040, the overall CR rate in the pembroli-
zumab treated group was 1.6% (N = 4 of 247). However,
in patients with a CPS ≥ 1 the CR was 2.0% (N = 4 of
196), and in patients with a TPS ≥ 50%, CR was 4.7%
(N = 3 of 64). Furthermore, PFS and RR also increased
with increasing PD-L1 expression (Table 1).
Conclusion
In the initial reported protocol-specified final analysis,
the KEYNOTE 040 study did not meet their
bio-statistical primary endpoint of OS [2]. However, the
survival data of a pending 12 patients, with no change to
the duration of the follow-up, made the difference in the
positive outcome reported in the protocol-specified final
analysis of KEYNOTE 040 [3, 4]. Although inter-study
comparisons must be put in the context of hidden biases
which always exist in trials, confounding factors which
may influence the clinical outcomes of the control arm
will continue to be a challenge as we move toward com-
binatorial immunotherapy trials and calls upon innova-
tive bio-statistical approaches and clinical trial design.
The observed clinical benefit with anti-PD1 therapies in
patients expressing PD-L1 within the tumor microenvir-
onment, may call for paradigm shifts to include bio-
marker expression as part of primary or secondary
bio-statistical endpoints in future clinical trials, rather
than as exploratory endpoints as traditionally done. This
is particularly important, since an increasing number of
CRs is being observed in the biomarker expressing
patient populations. Furthermore, given the impact on
costs and tolerability, patient selection has to take place
in order to provide individualized treatment, sparing
toxicities and maximizing clinical outcome. Immuno-
therapy when applied in the appropriate setting has the
potential to change the lives of cancer patients and
affords us further opportunities to explore personalized
treatment plans for our patients.
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P = 0,01 P = 0,0161
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